Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.
Company profile
Ticker
ITMR
Exchange
Website
CEO
Gilad Glick
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ITMR stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
27 Dec 21
EFFECT
Notice of effectiveness
27 Dec 21
EFFECT
Notice of effectiveness
27 Dec 21
POS AM
Prospectus update (post-effective amendment)
16 Dec 21
POS AM
Prospectus update (post-effective amendment)
16 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Dec 21
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Dec 21
25-NSE
Exchange delisting
16 Dec 21
6-K
Current report (foreign)
15 Dec 21
6-K
Itamar Medical Reports Third Quarter 2021 Financial Results
18 Nov 21
Latest ownership filings
SC 13G/A
Viola Growth Management Fund 2 Ltd.
14 Feb 22
SC 13G/A
Flynn James E
11 Feb 22
SC 13G/A
Phoenix Holdings Ltd.
4 Oct 21
SC 13G/A
Phoenix Holdings Ltd.
17 Jun 21
SC 13G
Migdal Insurance & Financial Holdings Ltd.
16 Feb 21
SC 13G
Redmile Group, LLC
16 Feb 21
SC 13G/A
YARON GIORA
16 Feb 21
SC 13G/A
MS Pace LP
12 Feb 21
SC 13G
Flynn James E
24 Nov 20
SC 13G/A
Itamar Medical Ltd.
18 Feb 20
Financial summary
Quarter (USD) | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2019
4.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 6.08 mm |
Total shares | 693.90 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Deerfield Management | 314.14 k | $2.75 mm |
Noked Capital | 178.01 k | $1.56 mm |
Noked Israel | 178.01 k | $1.56 mm |
Meitav Dash Investments | 23.74 k | $214.00 k |
Proequities | 0.00 | $0.00 |